Pfizer’s stock has been affected by falling COVID-19 vaccine sales, but recent earnings indicate a rebound, with a 3% revenue increase year-over-year and 14% growth excluding COVID-19 products. The acquisition of Seagen and strong sales of drugs like Vyndaqel and Eliquis have bolstered growth, prompting Pfizer to raise its full-year revenue projections to $59.5 billion-$62.5 billion. With an attractive 5.8% dividend yield and a favorable price-to-earnings ratio of 11, Pfizer looks appealing. However, regulatory risks in its pipeline and the necessity for a long-term strategy raise caution. Overall, strong fundamentals position Pfizer as a solid investment for long-term investors.